ENDRA Life Sciences Inc. (NASDAQ: NDRA) Stock Rockets 89%: What’s the Buzz?

If you are looking into stocks that made strong gains on Tuesday, then it could be difficult to look past ENDRA Life Sciences Inc. (NASDAQ: NDRA), which clocked gains of 89%. The stock is likely to be on the radars of investors this morning.

ENDRA Life Sciences Activates the TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

On October 22, the company announced that a post-market clinical study had been activated and the first patient had been scanned with EndRA Life Sciences’ TAEUS (thermoacoustic Enhanced Ultrasound) liver system. The process had taken place at the LMU University Hospital located in Munich. The hospital is regarded as one of the best research centers on the European continent.

The Study

The LMU University Hospital is currently conducting the postmarket clinical study with the aim of collecting data. The collected data would help in making an assessment on the liver fat measurement capacities of TAEUS in comparison to the MRI PDFF test, the standard in the space. The study would lead to the collection of real-world clinical evidence so as to establish the benefits of using the TAEUS system for the management of metabolic diseases.

The researchers from LMU would present the results from the clinical study at medical congresses, which would take place in the near future. Consequently, the results would also be published in peer-reviewed journals. It remains to be seen if the ENDRA Life Sciences stock can maintain the strong momentum today.

Management Comment

LMU University Hospital is one of Europe’s most highly regarded and influential academic research institutions, and we are delighted to commence this partnership. This collaboration is expected to build upon ENDRA’s growing portfolio of clinical data and support the company’s FDA De Novo submission targeted for mid-2025. Further, we believe the data will support the adoption of TAEUS technology as the reliable and accurate biomarker for liver fat, marking it as a first strategic step into Germany’s healthcare market, the largest in Europe,” stated Alexander Tokman, Acting Chief Executive Officer of ENDRA and Chairman of the Board.

Technicals

+/- EMA(20)	0.27 (+22.78%)
+/- SMA(50)	0.41 (-19.15%)
+/- SMA(200)	19.83 (-98.33%)